SCHEMBL23701607

SCHEMBL23701607

CN(CCCc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.41
MTOR P42345 1/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TP53 P04637 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
TACR1 P25103 2/20 0.38
GSK3B P49841 1/20 0.38
MAPK8 P45983 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701616 0.94 ABCG2 (0.42) DDX3XABCG2MTORNPC1RAB9A
SCHEMBL22556585 0.89 DDX3X (0.43) DDX3XABCG2MTORNPC1RAB9A
SCHEMBL23701532 0.89 MTOR (0.46) DDX3XABCG2MTORNPC1RAB9A
SCHEMBL23701555 0.85 DDX3X (0.42) DDX3XABCG2MTORRAB9AKMT2A
SCHEMBL25194709 0.85 ABCG2 (0.41) DDX3XABCG2MTORTP53FLT1
SCHEMBL22556378 0.85 DDX3X (0.39) DDX3XABCG2TP53FLT1KDR
SCHEMBL23701623 0.84 ABCG2 (0.41) DDX3XABCG2MTORTP53FLT1
SCHEMBL23701539 0.84 ABCG2 (0.42) DDX3XABCG2MTORTP53FLT1
SCHEMBL25189636 0.84 ABCG2 (0.40) DDX3XABCG2MTORTP53FLT1
SCHEMBL25190468 0.83 ABCG2 (0.40) DDX3XABCG2MTORTP53FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 DDX3X 611/4885ABCG2 2985/4885MTOR 219/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 DDX3X 611/4885ABCG2 2985/4885MTOR 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.